Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth (Q39664547)

13 September 2017

Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth (English)

1 reference

13 September 2017

1 reference

17

1 reference

13 September 2017

14

Mitch Dowsett

1 reference

13 September 2017

Robert S Tolhurst

1

1 reference

13 September 2017

Ross S Thomas

2

1 reference

13 September 2017

Fiona J Kyle

3

1 reference

13 September 2017

Hetal Patel

4

1 reference

13 September 2017

Manikandan Periyasamy

5

1 reference

13 September 2017

Andrew Photiou

6

1 reference

13 September 2017

Paul T R Thiruchelvam

7

1 reference

13 September 2017

Chun-Fui Lai

8

1 reference

13 September 2017

Marwa Al-Sabbagh

9

1 reference

13 September 2017

Rosemary A Fisher

10

1 reference

13 September 2017

Sayka Barry

11

1 reference

13 September 2017

Tatjana Crnogorac-Jurcevic

12

1 reference

13 September 2017

Lesley-Ann Martin

13

1 reference

13 September 2017

R Charles Coombes

15

1 reference

13 September 2017

Tahereh Kamalati

16

1 reference

13 September 2017

Laki Buluwela

18

1 reference

13 September 2017

language of work or name

English

0 references

publication date

22 August 2010

1 reference

Breast Cancer Research and Treatment

13 September 2017

1 reference

13 September 2017

128

1 reference

13 September 2017

2

1 reference

13 September 2017

357-368

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-010-1122-6

13 September 2017

0 references

cites work

Endocrine-responsive breast cancer and strategies for combating resistance

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Aromatase inhibitors for breast cancer: lessons from the laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

What do we know about the mechanisms of aromatase inhibitor resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

The loss of estrogen and progesterone receptor gene expression in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

A simplified system for generating recombinant adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Molecular determinants for the tissue specificity of SERMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Estrogen receptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Proteasomal regulation of nuclear receptor corepressor-mediated repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Estrogen down-regulation of the corepressor N-CoR: mechanism and implications for estrogen derepression of N-CoR-regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Bad expression predicts outcome in patients treated with tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1122-6

10.1007/S10549-010-1122-6

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference